No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC.
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC
DI MAIO, Massimo;
2016-01-01
Abstract
No biomarker is available to predict prognosis of patients with advanced ovarian cancer (AOC) and guide the choice of chemotherapy. We performed a prospective-retrospective biomarker study within the MITO2 trial on the treatment of AOC.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Oncotarget MITO2.pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
1.6 MB
Formato
Adobe PDF
|
1.6 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
